2025年半年报显示，公司营业收入达1316.71万元，同比增长11899.08%，主要得益于首个1类新药氘恩 扎鲁胺软胶囊获批上市，实现药品销售收入1306.88万元。 8月21日主力资金净流出573.18万元，近五日累计净流出965.56万元。 风险提示：股市有风险，投资需谨慎。 海创药业-U股价报61.39元，较前一交易日下跌1.08%。盘中最高触及63.29元，最低下探至61.10元，成 交额1.44亿元。 海创药业-U属于生物制品板块，专注于创新药研发。公司以靶向蛋白降解PROTAC技术和氘代技术为核 心，聚焦癌症、代谢性疾病等治疗领域。 ...

Core Viewpoint - The company, Jibeier, is demonstrating strong growth momentum driven by both innovative drug development and the upgrade of traditional products, with significant potential in the market for its existing products and upcoming innovations [1][10]. Group 1: Existing Products - The core product, Likujun Tablets, has undergone a five-year redevelopment process, optimizing its production process and increasing its purity from 94% to over 99.6%, securing two national invention patents valid until December 2041 [2][3]. - Likujun Tablets are widely used in the treatment of conditions associated with low white blood cell counts, with a significant market opportunity as it is now recognized as a recommended drug for malignant tumor treatment [2][3]. - In 2024, Likujun Tablets are expected to achieve sales revenue of 652 million yuan, with only about 20,000 patients currently covered in the tumor market, indicating a vast untapped market potential [3][4]. Group 2: Innovative Drug Pipeline - Jibeier has established three major technology platforms for drug development: deuterated drug research, compound formulation research, and liposome drug research, supporting a series of differentiated innovative drugs [5][6]. - The deuterated drug JJH201501, currently in the data summary phase of its Phase III clinical trial, shows promising results with lower doses achieving effects comparable to mainstream antidepressants, indicating a strong market potential in the antidepressant sector [6][7]. - The company is also developing multiple drugs based on its deuterated technology platform, including JJH201701 for acid reduction and JJH202301 for diabetes, creating a tiered research and development structure [7][8]. Group 3: Sales and Market Strategy - In 2024, the company achieved operating revenue of 897 million yuan and a net profit of 215 million yuan, reflecting a balanced focus on both research and sales [9]. - The company plans to enhance its marketing system and promote its existing products, particularly Likujun Tablets and Niqunlor Tablets, to accelerate sales growth [9][10]. - The Chinese innovative drug sector is currently experiencing a golden period of policy benefits, technological breakthroughs, and market demand, positioning Jibeier favorably for long-term growth [10].